Last Updated on November 20, 2021 by The Health Master
The company was informed via a statement that with this launch, it intends to revolutionise Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India.
The statement further said that Cipla’s Spirofy is a result of five years of meticulous in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India.
This advanced device ensures high accuracy and individual patient safety by using bacterial and viral filters.
Spirofy is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use.
The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a PDF version can be shared on the phone. Cipla will undertake physician training in the interpretation of spirometry results.
Commenting on the launch, Umang Vohra, MD and Global CEO, Cipla, said, “Cipla has been steadfastly focused on addressing the world’s growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD.
The Spirofy launch aims to help doctors across the country improve the lives of patients through accurate and affordable diagnosis.”
For informative videos by The Health Master, click on the below YouTube icon: